Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106459 | 0.86 | ADORA3 (0.70) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL3928268 | 0.85 | ADORA3 (0.71) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL3931207 | 0.84 | ADORA3 (0.64) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL14314147 | 0.84 | ADORA3 (0.67) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL5109505 | 0.83 | ADORA3 (0.68) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL5104064 | 0.82 | ADORA3 (0.61) | ADORA3ADORA2AADORA1TRPV1LMNA | |
| SCHEMBL5108128 | 0.81 | TRPV1 (0.62) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL14314148 | 0.81 | ADORA3 (0.62) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL5109109 | 0.81 | TRPV1 (0.65) | ADORA3ADORA2AADORA1TRPV1 | |
| SCHEMBL5108536 | 0.80 | ADORA2A (1.00) | ADORA3ADORA2AADORA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044086-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005303-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | ADORA3 819/4885ADORA2A 948/4885ADORA1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.